UNICREDIT BANK/CALL/NOVO-NORDISK B/1400/0.1/18.06.25 | Real-time BOERSE MUENCHEN 07:47:07 2024-06-05 am EDT | ||
| 0.52 EUR | +13.04% |
|
| Current month | +4.55% | ||
| 1 month | +39.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 0.52 | +13.04% |
| 24-06-04 | 0.46 | +9.52% |
| 24-06-03 | 0.42 | -4.55% |
| 24-05-31 | 0.44 | +2.33% |
| 24-05-30 | 0.43 | +7.50% |
Real-time BOERSE MUENCHEN
Last update June 05, 2024 at 07:47 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD31CL |
| ISIN | DE000HD31CL2 |
| Date issued | 2024-02-26 |
| Strike | 1,400 kr |
| Maturity | 2025-06-18 (378 Days) |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.78 € |
|---|---|
| Lowest since issue | 0.3 € |
| Spread | 0.01 € |
| Spread % | 1.89% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
920
DKK
Spread / Average Target
-1.73%
- Stock Market
- Warrants
- Warrant
